Laxou

People with mental disorders often face stigmatizing attitudes, which can lead them to isolate themselves and interfere with their care and recovery. This trial focuses on reducing self-stigma, a form of stigma individuals apply to themselves, which is linked to increased shame, lowered coping skills, social avoidance, and worse clinical outcomes. Compassion Focused Therapy CFT, a type of cognitive behavioral therapy aimed at reducing shame and fostering self-compassion, is being evaluated for its effectiveness in individuals with high levels of self-stigma. The study compares three groups one receiving group-based Compassion Focused Therapy, another undergoing a psychoeducation program called Ending Self Stigma ESS, and a third receiving treatment as usual TAU. The CFT program includes psychoeducation on compassion and emotion regulation, experiential exercises during sessions, and guided practices with video support between sessions. The ESS program provides education on stigma and self-stigma and encourages home exercises to improve self-esteem. Participants will be assessed for internalized stigma using the Internalized Stigma of Mental Illness inventory ISMI at the start and monthly for three months. The study involves psychiatric evaluations to monitor symptom severity and ensure safety. Researchers will evaluate changes in self-stigma levels and the acceptability of the treatments over the study period. The trial is sponsored by the University Hospital in Strasbourg, France, and is ongoing with a planned end date in March 2028.

Researchers are evaluating a Mobile Perinatal Psychiatry Team EMPPer that supports children aged 0 to 3 years and their parents by providing psychiatric care directly to families facing difficulties. This approach aims to improve early detection and intervention for developmental and neurodevelopmental disorders, promoting better psychomotor development and child language outcomes. The study compares areas with and without EMPPer services and examines its impact on child development and healthcare costs. The intervention involves a mobile team visiting families in a designated region Meurthe-et-Moselle Sud to facilitate access to psychiatric care, especially for vulnerable populations. Children in this area receive the EMPPer intervention, while children in comparison regions Strasbourg and Reims do not. The study uses a quasi-experimental design including before-and-after comparisons and process evaluations to assess implementation, impact, and cost-effectiveness. Participants include children aged 0 to 3 years and their families. Data collection occurs at ages 2 and 4 years, including psychomotor development assessments, language delay evaluations, satisfaction and therapeutic alliance questionnaires, and healthcare cost analyses. The study uses observations, interviews, and standardized tools to understand the interventions effects and sustainability over time, with a total follow-up period extending to 4 years.

Researchers are evaluating whether the EMOCARE emotional monitoring software provides consistent results compared to standard questionnaires used to assess emotional states in patients with mild to moderately severe depressive episodes. This study aims to understand how well EMOCARE matches tools like PHQ-9, MADRS, GAD-7, BDI-II, and EQ-5D-5L, and to learn about any medical issues participants may experience when using this passive monitoring software. The study focuses on outpatients with major depressive disorder who use digital devices regularly. Participants will install the EMOCARE software on a smartphone, computer, or similar device and can activate or deactivate it during a six-week follow-up period. They will attend two scheduled visits at the centerone at the start and one six weeks laterto complete questionnaires and be interviewed by a doctor. Additionally, participants will complete questionnaires independently at home two and four weeks after the first appointment. A phone call from the doctor will take place three weeks after the initial visit to check on how participants are feeling. Participants will also keep a diary of symptoms, medical consultations, and any medication changes. Throughout the study, researchers will collect and compare scores from EMOCARE and various questionnaires at multiple time points, including baseline, two, four, and six weeks. They will monitor the acceptability of the device, adverse events, and changes in depression severity. The main outcomes measured are changes in EMOCARE scores and PHQ-9 scores from baseline to six weeks. The total participation duration is six weeks, with regular monitoring and assessments to understand emotional states and device use.

Researchers are exploring the lived experiences of individuals aged 15 to 30 who are at ultra-high risk UHR or experiencing a first episode of psychosis FEP. This qualitative study aims to describe these experiences during participation in a group-based mindfulness intervention and to identify any potential adverse effects of this type of intervention. The study is sponsored by the Centre Psychothrapique de Nancy and focuses on understanding the impact of mindfulness on social functioning and psychosis risk. Participants take part in a group mindfulness-based program, after which they undergo a qualitative interview. The interview is analyzed using the IPSE Inductive Process to analyze the Structure of lived Experience method to capture detailed personal experiences related to the intervention. The interview occurs between one week and three months following the final mindfulness session. During the study, researchers assess participants social functioning and their experiences with the mindfulness program through these interviews. The primary outcome is the detailed description of participants lived experiences obtained via qualitative interviews. The total duration of involvement varies depending on when the interview takes place after the mindfulness program concludes, with no additional treatments or follow-up mentioned.

People with mental disorders tend to smoke more than the general population, which contributes to a significant reduction in their life expectancy by 10 to 20 years, mainly due to heart and lung diseases such as bronchial cancers. Despite this, smoking cessation efforts tailored for psychiatric patients are limited, as smoking is often overlooked or accepted in mental health care settings. This study aims to assess a smoking cessation program called Tabapsy designed with input from mental health users, professionals, and general practitioners, focusing on adult patients receiving outpatient psychiatric care. The Tabapsy intervention includes a campaign promoting smoking cessation within psychiatric medical psychological centers CMPs and a series of supportive activities. These activities involve an initial information meeting to boost motivation, an assessment workshop to evaluate nicotine dependence and create personalized quitting plans, five thematic workshops covering nicotine replacement, emotional management, weight control, physical activity, and manual tasks, and peer support groups for shared experiences. A dedicated facilitator will lead these sessions, supported by an online resource website. The study compares the intervention against usual care in a national cluster-randomized trial involving psychiatric sectors. Participants who smoke regularly and consent will complete questionnaires via a web app at the start, 3 months, and 6 months, with additional surveys for those in the intervention group. The questionnaires cover smoking habits, dependence, motivation, cessation aid use, mental and physical well-being, and knowledge about tobacco. The main outcome is smoking cessation lasting at least 7 days at 3 months. Secondary outcomes include cost-effectiveness, implementation, quit attempts, and satisfaction. A total of 6,250 participants will be enrolled over 12 months across 22 sectors.

Researchers are studying language disorders in people with psychosis, including those at risk, experiencing a first episode, or diagnosed with schizophrenia. The study aims to understand how language difficulties affect communication and relate to thought disorders and neuropsychological symptoms. It also explores interactions between working memory and syntax abilities in these patients. The research compares patients language skills with those of healthy volunteers without mental or language disorders. Participants are divided into groups those with early psychotic symptoms ARMS and FEP, patients with schizophrenia, and healthy controls. Each group undergoes language assessments evaluating various language domains such as phonology, semantics, and pragmatics. Schizophrenia patients additionally complete the TLC scale, while all participants complete the Cannabis Abuse Screening Test CAST. Healthy controls also complete a psychiatric screening using the MINI. During the study, participants undergo comprehensive evaluations including language tests, psychiatric interviews, and neuropsychological assessments. Researchers measure language assessment performance, severity of speech disorganization, thought disorder symptoms, and working memory capacities. Data from medical records are analyzed for associations between language skills and psychiatric symptoms. The study enrollment includes participants aged 16 to 55 years and involves one day of assessments.